Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in Austria / NCT03660969
Active, not recruiting Observational

Reliability of Cardiac Troponins for the Diagnosis of Myocardial Infarction in the Presence of Skeletal Muscle Disease

NCT03660969 · tracked via the Priya Life Science Austria tracker
Sponsor
University Hospital, Basel, Switzerland
Phase
Observational
Started
2018-01-01
Last updated
2026-09-21

Condition(s) studied

MyopathyMuscle WeaknessMuscle DamageMuscle SpasticityMuscle CrampMuscle InjuryMuscle SorenessMuscle Atrophy

Study summary

Visits to the emergency department (ED) for chest pain are extremely common and require a safe, rapid and efficacious treatment algorithm to exclude a possible AMI. These diagnostic algorithms are partly based on an important laboratory value, which showed growing utility in the diagnostic and prognostic of many cardiovascular diseases in the last years : cardiac troponin.

However, some patients with muscle disease often present with unexplained elevated high-sensitive cardiac Troponin T (hs-cTnT) levels in the absence of cardiac disease. The investigators aim at the characterization of the behaviour of this biomarker and its alternative (high-sensitive cardiac Troponin I), which will have important clinical implications on patients management.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Diagnostic or suspicion of muscle disease as presence of specified keyword in patient's file or as screened by colleagues of the rheumatology, neuromuscular or other medical clinics. * Patient consent available Exclusion Criteria: * Patient's refusal * Age \<18 years old * Terminal kidney insufficiency with need for dialysis. * Temporary exclusion criteria : Acute health condition such as myocardial infarction, patients presenting with a major trauma, a sepsis, patients shortly after cardiac surgery, and patients in shock (\>100 bpm, \<90 systolic BP, evidence of organ dysfunction).

Primary outcome measure(s)

  • Comparison of cTnT and cTnI levels as measured by different hs-cTn assays in patients with skeletal muscle disease. — 1 year

Trial sites (5)

FacilityCityRegionStatus
Medical University Innsbruck Innsbruck Innsbruck
University Hospital Basel Basel Basel
Canton Hospital of Aarau Aarau Canton of Aargau
University Hospital Zürich Zurich Canton of Zurich
Inselspital Bern Bern Switzerland

More University Hospital, Basel, Switzerland trials in Austria

Risk of Recurrent CeAD After Pregnancy Recruiting
Implementation of a Clinical Screening and Response System for Cardiac Complications After Noncardiac Surgery Active, not recruiting
The LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated Lymphedema Recruiting
Early Detection and IntervenTion in Heart Failure Recruiting
The OPBC-07/microNAC Study Active, not recruiting

Other trials for the same condition

Improved Muscle Metabolism by Combination of Muscle Activation and Protein Substitution ( IMEMPRO ) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03660969 on ClinicalTrials.gov ↗ ← All trials in Austria